No Data
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
Lineage Explores Connection Between Food Infrastructure and Economic Development in New Research by Economist Impact
Lineage Cell Price Target Lowered to $2 From $3 at D. Boral Capital
Lineage Cell Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of up to a $66 Million Registered Direct Offering. Also, D Boral Capital Maintained a Buy Rating on the Stock and Lowered Its Price Target From $3 to $2.
Trump Media Saw the Largest Increase in Short Interest in October
Lineage Cell Therapeutics Entered Into Definitive Agreements With Certain Institutional Investors And With Broadwood Partners, L.P. For The Purchase And Sale Of Up To An Aggregate Of 39,473,688 Of Lineage's Common Shares And Accompanying Warrants To...
No Data
No Data
